Chikungunya Research Articles

Chikungunya fever.

Chikungunya virus is widespread throughout the tropics, where it causes recurrent outbreaks of chikungunya fever. In recent years, outbreaks have afflicted populations in East and Central Africa, South America and Southeast Asia. The virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Chikungunya fever is characterized by severe arthralgia and myalgia that can persist for years and have considerable detrimental effects on health, quality of life and economic productivity. The effects of climate change as well as increased globalization of commerce and travel have led to growth of the habitat of Aedes mosquitoes. As a result, increasing numbers of people will be at risk of chikungunya fever in the coming years. In the absence of specific antiviral treatments and with vaccines still in development, surveillance and vector control are essential to suppress re-emergence and epidemics.

Immunological impact of cytokines on the chikungunya virus pathophysiology: A literature narrative review.

The chikungunya virus (CHIKV) is a member of the genus Alphavirus, family Togaviridae. CHIKV causes an acute systemic febrile condition, accompanied by severe polyarthralgia, intense muscle pain, and maculopapular exanthema, which may still occur in many patients. In rare cases, unusual symptoms may occur, eventually worsening the condition and resulting in a fatal outcome. It is a single-stranded, non-segmented RNA virus with a genome of approximately 11,805 nucleotides that organises a genetic and molecular chain that encodes non-structural proteins (nsP1, nsP2, nsP3, nsP4) and structural proteins (E3, E2, 6K, and E1). The fundamental role of immune response in the evolution of the disease is known. Understanding the role of immune response in the pathogenesis of CHIKV infection is challenging. In this context, innate and adaptive immune responses establish a connective interface that induces the production of various mediators that modulate the strategy of inhibiting viral replication. However, the immune escape articulated by the virus indicates that the action of pro-and anti-inflammatory cytokines contributes to the worsening of the disease and potentiates tissue damage with joint involvement. In this review, we discuss the role of the primary pro-and anti-inflammatory cytokines in the immunopathological processes of chikungunya fever.

Identification of three medically important mosquito species using Raman spectroscopy

AbstractAccurate identification of disease vectors is crucial when collecting epidemiological data. In mosquitoes, which transmit diseases like malaria, yellow fever, chikungunya, and dengue fever, identification mainly relies on the observation of external morphological features at different life cycle stages. This process is tedious and labor‐intensive. In this paper, the utility of Raman spectroscopy to discriminate and classify three mosquito species, namely,Aedes aegypti,Anopheles gambiae,andCulex quinquefasciatus,is presented. The three species were chosen to represent two subfamilies of medically important mosquitoes, that is, the Anophelinae and the Culicinae. The study is primarily a proof of concept on the potential of Raman spectroscopy in mosquito taxonomy. A dispersive Raman microscope was used to record spectra from the legs (femur and tibia) of fresh anesthetized laboratory‐bred mosquitoes. Broad peaks centered around 1400, 1590, and 2060 cm−1dominated the spectra. These peaks, attributed to cuticular melanin, were important in mosquito discrimination. Variance threshold (VT) and principal component analysis (PCA) were used for feature selection and feature extraction, respectively. The extracted features were then used to train and test linear discriminant analysis (LDA) and quadratic discriminant analysis (QDA) classifiers. VT/PCA/QDA achieved an overall accuracy of 94%, a sensitivity of 87%, and a specificity of 96%, whereas VT/PCA/LDA attained an accuracy of 85%, a sensitivity of 69%, and a specificity of 90%. The success of these relatively simple classification models on Raman spectroscopy data lays the ground for future development of machine learning models that may include discrimination of cryptic species.

The protein disulfide isomerase inhibitor 3-methyltoxoflavin inhibits Chikungunya virus.

Chikungunya virus (CHIKV) is the etiological agent of chikungunya fever, a (re)emerging arbovirus infection, that causes severe and often persistent arthritis, as well as representing a serious health concern worldwide for which no antivirals are currently available. Despite efforts over the last decade to identify and optimize new inhibitors or to reposition existing drugs, no compound has progressed to clinical trials for CHIKV and current prophylaxis is based on vector control, which has shown limited success in containing the virus. Our efforts to rectify this situation were initiated by screening 36 compounds using a replicon system and ultimately identified the natural product derivative 3-methyltoxoflavin with activity against CHIKV using a cell-based assay (EC50 200nM, SI=17 in Huh-7 cells). We have additionally screened 3-methyltoxoflavin against a panel of 17 viruses and showed that it only additionally demonstrated inhibition of the yellow fever virus (EC50 370nM, SI=3.2 in Huh-7 cells). We have also showed that 3-methyltoxoflavin has excellent in vitro human and mouse microsomal metabolic stability, good solubility and high Caco-2 permeability and it is not likely to be a P-glycoprotein substrate. In summary, we demonstrate that 3-methyltoxoflavin has activity against CHIKV, good in vitro absorption, distribution, metabolism and excretion (ADME) properties as well as good calculated physicochemical properties and may represent a valuable starting point for future optimization to develop inhibitors for this and other related viruses.

A Case of Triple-Infection with SARS-CoV-2, Chikungunya, and Dengue Fever in a Returning Traveler

Chikungunya (CHIKV) and dengue (DENV) fever are caused by arboviruses with a shared vector and often overlap in tropical endemic areas. COVID-19, caused by the SARS-CoV-2 virus, has a similar presentation to CHIKV and DENV. The case of a 39-year-old woman with a triple viral infection (DENV, CHIKV, and SARS-CoV-2) is presented. Co-infection with endemic viruses post-travel is likely underreported due to overlapping clinical presentations and timelines. Awareness of illness in returning travelers and prompt co-infection diagnosis are needed to optimize patient outcomes.

Fever of unknown origin as a form of presentation of chikungunya fever in a young male

La fiebre chikungunya es una enfermedad viral descrita por primera vez en 1952. Actualmente se informan brotes esporádicos de fiebre chikungunya a nivel país (abril 2022). Presentamos el caso de un varón joven con fiebre chikungunya en fase subaguda la cual se presentó al ingreso hospitalario como fiebre de origen desconocido.

Facility-Based Cross-Sectional Survey on Aedes-Borne Diseases and Associated Symptoms among Febrile Patients During the 2019 Dengue Outbreak in Moshi Rural District, Tanzania

Background: Diseases caused by Aedes-borne viruses, such as; dengue, chikungunya, and Zika are emerging and re- emerging in different parts of the world. Tanzania has experienced several dengue outbreaks since 2010. The present study aims to determine the seroprevalence and associated symptoms of dengue and chikungunya fever in the Moshi rural district during the 2019 dengue outbreak. Methodology: A facility-based cross-sectional survey was conducted in 15 health facilities in the Moshi Rural district. A total of 397 participants with malaria-like symptoms were enrolled. Participants were screened for seropositivity towards dengue and chikungunya Immunoglobulin G and M (IgG and IgM) using ELISA-based kits. Results: Out of 397 participants, 28 (7.1 %) and 8 (2.0%) were dengue IgM and IgG positive respectively. Chikungunya IgM positives were 34 (8.6%). The most commonly reported symptoms were; headache 189 (27.7%), joint pains 132 (19.4%) and muscle pain 106 (15.5%). Factors such as being a farmer and history of travelling to outside regions was associated with dengue IgM seropositivity (p<.05). Conclusion: Aedes-borne illnesses appear to be endemic in the area, with IgG antibodies against the Chikungunya virus being more prevalent among study participants. These results provide an understanding of arboviral diseases as well as provide an early warning signal on the risk of transmission in north Tanzania. The results inform the allocation of local and national public health intervention to prevent future outbreaks.

A sero-epidemiological investigation of West Nile virus among patients without any records of their symptoms from three different hospitals from Tunisia

West Nile virus is one of the most known arboviruses around the world, along with Dengue virus, Toscana virus, Chikungunya (CHIK). In Tunisia, many epidemics of WNV had occurred in the past. The last one dated from 2018. The aim of our work was to perform a sero-epidemiological investigation on WNV without any records of their symptoms from three different hospitals from Tunisia. Patients without any records of their symptoms of the infection of West Nile Virus (WNV) infection were included in the period from October 2017 to January 2020 from three different Virology departments in the country (the Military Hospital in Tunis, Fattouma Bourguiba Hospital in Monastir and Sahloul Hospital in Sousse). A venous blood sample was taken from all patients at the bend of the elbow using a sterile syringe under aseptic conditions. Serological investigation for WNV was conducted through ELISA and IFI assays. RT-PCR was used to confirm the infection. The study included 353 patients. Twenty-eighty percent (28.8%) of the population were tested positive for IgM antibodies, males were having less positive antibodies than women (24.6% vs. 36.3%, p<0.05). In the city of Sousse, positive IgM were found more than in the other cities. As for IgG, 19.2% of the patients were having positive antibodies. No significant association was found between genders (p>0.05). One quarter of the IgM antibodies were tested positive using IFI technique, with no difference between genders (p>0.05). Only 9.2% of the samples were positive by PCR. Our results highlight the importance of establishing sustainable entomological systems and effective clinical ones and of promoting appropriate biological control strategies to optimize the limitation of the circulation of WNV as well as other arboviruses to inhibit their harmful effects on health.

Role of the Microbiome in Aedes spp. Vector Competence: What Do We Know?

Aedes aegypti and Aedes albopictus are the vectors of important arboviruses: dengue fever, chikungunya, Zika, and yellow fever. Female mosquitoes acquire arboviruses by feeding on the infected host blood, thus being able to transmit it to their offspring. The intrinsic ability of a vector to infect itself and transmit a pathogen is known as vector competence. Several factors influence the susceptibility of these females to be infected by these arboviruses, such as the activation of the innate immune system through the Toll, immunodeficiency (Imd), JAK-STAT pathways, and the interference of specific antiviral response pathways of RNAi. It is also believed that the presence of non-pathogenic microorganisms in the microbiota of these arthropods could influence this immune response, as it provides a baseline activation of the innate immune system, which may generate resistance against arboviruses. In addition, this microbiome has direct action against arboviruses, mainly due to the ability of Wolbachia spp. to block viral genome replication, added to the competition for resources within the mosquito organism. Despite major advances in the area, studies are still needed to evaluate the microbiota profiles of Aedes spp. and their vector competence, as well as further exploration of the individual roles of microbiome components in activating the innate immune system.

Geographic clustering of travel-acquired infections in Ontario, Canada, 2008-2020.

As the frequency of international travel increases, more individuals are at risk of travel-acquired infections (TAIs). In this ecological study of over 170,000 unique tests from Public Health Ontario's laboratory, we reviewed all laboratory-reported cases of malaria, dengue, chikungunya, and enteric fever in Ontario, Canada between 2008-2020 to identify high-resolution geographical clusters for potential targeted pre-travel prevention. Smoothed standardized incidence ratios (SIRs) and 95% posterior credible intervals (CIs) were estimated using a spatial Bayesian hierarchical model. High- and low-incidence areas were described using data from the 2016 Census based on the home forward sortation area of patients testing positive. A second model was used to estimate the association between drivetime to the nearest travel clinic and incidence of TAI within high-incidence areas. There were 6,114 microbiologically confirmed TAIs across Ontario over the study period. There was spatial clustering of TAIs (Moran's I = 0.59, p<0.0001). Compared to low-incidence areas, high-incidence areas had higher proportions of immigrants (p<0.0001), were lower income (p = 0.0027), had higher levels of university education (p<0.0001), and less knowledge of English/French languages (p<0.0001). In the high-incidence Greater Toronto Area (GTA), each minute increase in drive time to the closest travel clinic was associated with a 3% reduction in TAI incidence (95% CI 1-6%). While urban neighbourhoods in the GTA had the highest burden of TAIs, geographic proximity to a travel clinic in the GTA was not associated with an area-level incidence reduction in TAI. This suggests other barriers to seeking and adhering to pre-travel advice.

Construction and immunogenicity of an mRNA vaccine against chikungunya virus.

Chikungunya fever (CHIKF) has spread to more than 100 countries worldwide, with frequent outbreaks in Europe and the Americas in recent years. Despite the relatively low lethality of infection, patients can suffer from long-term sequelae. Until now, no available vaccines have been approved for use; however, increasing attention is being paid to the development of vaccines against chikungunya virus (CHIKV), and the World Health Organization has included vaccine development in the initial blueprint deliverables. Here, we developed an mRNA vaccine using the nucleotide sequence encoding structural proteins of CHIKV. And immunogenicity was evaluated by neutralization assay, Enzyme-linked immunospot assay and Intracellular cytokine staining. The results showed that the encoded proteins elicited high levels of neutralizing antibody titers and T cell-mediated cellular immune responses in mice. Moreover, compared with the wild-type vaccine, the codon-optimized vaccine elicited robust CD8+ T-cell responses and mild neutralizing antibody titers. In addition, higher levels of neutralizing antibody titers and T-cell immune responses were obtained using a homologous booster mRNA vaccine regimen of three different homologous or heterologous booster immunization strategies. Thus, this study provides assessment data to develop vaccine candidates and explore the effectiveness of the prime-boost approach.

Chikungunya Virus: Priority Pathogen or Passing Trend?

Chikungunya virus (CHIKV) is considered a priority pathogen and a major threat to global health. While CHIKV infections may be asymptomatic, symptomatic patients can develop chikungunya fever (CHIKF) characterized by severe arthralgia which often transitions into incapacitating arthritis that could last for years and lead to significant loss in health-related quality of life. Yet, Chikungunya fever (CHIKF) remains a neglected tropical disease due to its complex epidemiology and the misrepresentation of its incidence and disease burden worldwide. Transmitted to humans by infected Aedes mosquitoes, CHIKV has dramatically expanded its geographic distribution to over 100 countries, causing large-scale outbreaks around the world and putting more than half of the population of the world at risk of infection. More than 50 years have passed since the first CHIKV vaccine was reported to be in development. Despite this, there is no licensed vaccine or antiviral treatments against CHIKV to date. In this review, we highlight the clinical relevance of developing chikungunya vaccines by discussing the poor understanding of long-term disease burden in CHIKV endemic countries, the complexity of CHIKV epidemiological surveillance, and emphasising the impact of the global emergence of CHIKV infections. Additionally, our review focuses on the recent progress of chikungunya vaccines in development, providing insight into the most advanced vaccine candidates in the pipeline and the potential implications of their roll-out.

Pathogenesis of chronic chikungunya arthritis: Resemblances and links with rheumatoid arthritis.

Chikungunya virus (CHIKV) infection results from transmission by the mosquito vector. Following an incubation period of 5-7 days, patients develop an acute febrile illness, chikungunya fever (CHIKF), characterized by high fevers, maculopapular rash, headaches, polyarthritis/arthralgias, myalgias, nausea, vomiting, and diarrhea. Joint pain is often severe, and most often involves the hands, the wrists, the ankles, and the metatarsal-phalangeal joints of the feet. Many patients recover within several weeks, but up to 50% develop chronic joint pain and swelling for more than 12 weeks, then we refer to these symptoms as chronic chikungunya arthritis (CCA). The pathogenesis of CCA is not well understood. In this article, we suggest that mesenchymal stem cells (MSCs) may play an important role in this pathogenesis. This heterogeneous group of multipotent cells, morphologically similar to fibroblasts, may undergo epigenetic changes capable of generating aberrant progenies. However, we believe that there is no need for a latent infection. In our pathogenic hypothesis, CHIKV infection of MSCs would cause epigenetic changes both in MSCs themselves and in their progenies, without the need for reactivation of dormant viruses.

Tomato flu outbreak in India: a need for precautionary measures in dental treatment.

Dear Editor, As of 21 August 2022, India has recorded 82 cases of Tomato flu (TF) in youngsters under the age of 5 and 26 cases in children aged below 10. This has alerted people all around the world to the possibility of a fresh epidemic in India. It may be a complication of childhood dengue or chikungunya fever rather than a viral infection1. It may be a novel strain of the viral hand, foot, and mouth disease caused by Coxsackie virus2,3. Children are primarily vulnerable since viral infections are common in them; but, if they are not treated and avoided, they may also have harmful consequences on adults4. The TF is very contagious, much like other influenza types. Close touch is the most probable means of transmission. Its primary signs and symptoms resemble those of chikungunya, including high fever, rashes, and agonizing joint pain. The painful, red blisters that spread widely and finally grew to the size of tomatoes gave the disease its name. These blisters resemble those that patients who have the monkeypox virus experience. Additional symptoms and indicators include fatigue, nausea, vomiting, diarrhea, fever, dehydration, joint swelling, and body aches, which are comparable to those of other viral infections. In addition, these symptoms are similar to those of other viral illnesses including dengue4,5. Five to 7 days after the onset of symptoms, confinement must be utilized to stop the virus from spreading. The best preventative strategy involves practicing excellent hygiene, sanitizing the nearby area, and preventing the sick child from exchanging items with other kids who are well. Drug repurposing and vaccination are the most effective and economical ways to protect the general populace against viral infections, especially in children, the elderly, and those with compromised immune systems. There are currently no antiviral drugs or vaccinations that can be used to treat or prevent TF. To better comprehend the morphology of the virus and possible therapeutic options, long-term follow-up is required6. Dental treatment in patients with TF can be very challenging. This infection can start as a rash or blister in perioral and oral mucosa also, in which cases the role of dentists in identifying this in their differential diagnoses and guiding the patients to appropriate medical care becomes paramount. Active dental treatment including endodontic, periodontic, prosthodontic, and restorative procedures should be deferred until complete recovery. However, emergency extraction procedures should be carried out with total personal protection equipment. Biomedical waste and tissues should be properly discarded by protected incineration. Antibiotics and analgesics can be prescribed to manage pain. Patients should be instructed to practice meticulous oral hygiene with individual toothbrushes. These toothbrushes should be discarded immediately after recovery from TF illness. In India, with 70% population distributed in the rural areas with dental clinics of less stringent practices followed, the spread of TF is largely expected. Therefore, a proper guidelines is essential to curb its transmission. To enlighten clinicians, medical personnel’s and other hospital staff’s readers further, we share a few more additional suggestions that are followed at our dental clinic. It’s crucial to use protective gear, such as personal protective equipment and N95 respirators while working with procedures that create aerosols. Restricting the use of tower fans, air blowers, and air conditioners in hospitals. Reducing the number of outpatient visits by giving high priority to patients who need urgent care, such as trauma patients. Instead of communal treatment space, patients who require treatments should get them in a private setting. Patients with suspected or confirmed TF should postpone elective dental operations until they are no longer infectious. Limited contact with all tools and supplies used to treat TF patients. Equipment used in patient care must be adequately sterilized. Overall, restraining the spread of TF in outpatient and trauma units, maintaining regular surgical volumes, and providing treatment to all patients regardless of health should be the key healthcare objectives. Ethical approval None. Sources of funding None. Authors’ contribution All authors devised the concept, performed the literature search, and drafted the letter. Conflicts of interest disclosure The authors declare that they have no financial conflict of interest with regard to the content of this report. Research registration unique identifying number (UIN) None. Guarantor None. Data Statement None.

Outbreak of tomato flu in India raising concerns: is it a false alarm or are we welcoming a new pandemic?

Outbreak of tomato flu in India raising concerns: is it a false alarm or are we welcoming a new pandemic?

Tackling chikungunya and dengue crisis in Paraguay amidst COVID-19: an epidemiological alert - a correspondence.

Tackling chikungunya and dengue crisis in Paraguay amidst COVID-19: an epidemiological alert - a correspondence.

Susceptibility of various cell lines to the &lt;i&gt;Chikungunya virus&lt;/i&gt; and method selection for commercial-scale production of viral material

An increase in cases of chikungunya fever is reported in the Caribbean, Central and South America, and Southeast Asia. As there is no specific treatment for this disease and the only available treatment is symptomatic, it is very relevant to develop vaccines against chikungunya fever. To develop an inactivated whole-virion vaccine against the disease, it is important to choose a susceptible cell culture that both provides high virus yields and is used for vaccine production.The aim of the study was to evaluate the susceptibility of multiple cell lines to Chikungunya virus infection and to select the monolayer culture method with the highest virus accumulation and yield.Materials and methods. The study used the CHIKV_Nic strain of the Chikungunya virus and cell lines C6/36 (for virus titration), CEF, MRC-5, Vero, and 4647. While choosing the culture method, the authors used culture flasks, a cell factory, and roller bottles. The authors determined the susceptibility of the cell lines to viral infection by the degree of accumulation of the infectious agent in the culture fluid. The results of virus titration were calculated on day 5 on the basis of a pronounced viral cytopathic effect.Results. The Vero and 4647 cell lines demonstrated the highest susceptibility to infection and virus concentrations in the culture fluid. The СEF and MRC-5 cell lines accumulated the virus at lower concentrations. The maximum virus titres (7.10–7.75 log10 TCID50/mL) were observed in the culture fluid 48 h after infection. The optimal multiplicity of infection (MOI) ranged between 0.001 and 0.0001 MOI/cell. At 0.0001 MOI/cell, the virus accumulated in the Vero cells cultured in roller bottles on day 2, with the maximum virus titre being 8.6±0.2 log10 TCID50/mL.Conclusions. Vero cells meet the safety and stability requirements set for the production of chikungunya vaccines. The study determined the minimum MOI of the Chikungunya virus for cell culture. The roller bottle culture method provides the highest cell culture yield and the highest titre of the virus in the culture fluid.

Peruvian plant resources as potential natural controllers of adult Aedes aegypti

Aedes aegypti is an important vector of tropical diseases like Dengue, Zika, Chikungunya, and Yellow Fever and affects mainly countries located in tropical and subtropical zones, including Peru. Synthetic insecticides are used to control this vector, but they also cause a residual effect on the environment, whereas the vector has developed resistance to these compounds, so there is a current need to search for new control alternatives, such as the use of abundant natural resources. Therefore, this work aimed to evaluate the biocidal activity of extracts and oils from Cymbopogum citratus, Rosmarinus officinalis, and Minthostachys mollis on adult Aedes aegypti, as well as to evaluate their quality parameters. Furthermore, the chemical profile of the three species was assessed by ultra-high-performance liquid chromatography coupled with mass spectrometry (LC-MS/MS). The results showed that the aqueous/ethanolic extracts and the essential oils from the three evaluated species presented a biocidal effect on adult A. aegypti. Regarding the analysis of the chemical profile, 15 compounds were identified in R. officinalis, while 29 compounds were identified from C. citratus and 30 compounds from M. mollis. Moreover, the extracts and oils presented quality parameters according to standards. In conclusion, the biocidal potential of the C. citratus, R. officinalis, and M. mollis on A. aegypti adults was reported so that they can be seen as a real natural alternative for the control of tropical diseases transmitted by this vector so that plant products are more eco-friendly and subject to lower resistance by target organisms.

Dengue-chikungunya infection in the tertiary care hospital of northern India: Cross-sectional latent class cluster analysis in viral infection

Cases of dengue and chikungunya fever are escalating all over India. Both viruses share a common vector, the “Aedes” mosquito. Due to similar clinical symptoms, both the dengue (DENV) and chikungunya (CHIKV) virus can circulate as co-infection. There is very limited data available on dengue-chikungunya co-infection in Uttarakhand, India. The purpose of this study was to determine the seroprevalence of dengue and chikungunya virus infections, as well as their co-infection, in patients presenting with clinical symptoms. Serum samples of clinically suspected patients from the tertiary care hospital of Uttarakhand were collected, and Latent Class Cluster Analysis was performed for clinical profiling. ELISA was performed for DENV and CHIKV. 279 cases were enrolled, out of which 222 (79.5%) came positive for dengue NS1 Ag, 143 (51.2%) for dengue IgM, 98 (35.1%) for IgG followed by 16 (5.7%) of CHIKV IgM, and 4 (1.4%) were NS1 Ag with CHIKV IgM. Among the clinical features, fever (n = 270, 96.8%) was the most common symptom in all suspected dengue and chikungunya cases. Other symptoms like chills (n = 254, 91.0%), arthralgia (n = 241, 86.4%), and headache (n = 240, 86.0%) were present in a significant number. Results showed fewer odds of getting both DENV and CHIKV infection simultaneously, but the risk is still not negligible. This study explores the clinical presentation of the suspected dengue-chikungunya case. The increasing incidence of dengue and chikungunya and their co-infection necessitate the authorities' active surveillance of endemic regions and effective patient care management.

Epidemiology of dengue, chikungunya and Zika virus infections in travellers: A 16-year retrospective descriptive study at a tertiary care centre in Prague, Czech Republic.

This study aims to describe the epidemiological characteristics of imported cases of dengue (DEN), chikungunya (CHIK), and Zika virus (ZIKV) infections in Czech travellers. This single-centre descriptive study has retrospectively analysed data of patients with laboratory confirmed DEN, CHIK, and ZIKV infections diagnosed at the Department of Infectious, Parasitic and Tropical Diseases of the University Hospital Bulovka in Prague, Czech Republic from 2004 to 2019. The study included a total of 313 patients with DEN, 30 with CHIK, and 19 with ZIKV infections. Most patients travelled as tourists:263 (84.0%), 28 (93.3%), and 17 (89.5%), respectively (p = 0.337). The median duration of stay was 20 (IQR 14-27), 21 (IQR 14-29), and 15 days (IQR 14-43), respectively (p = 0.935). Peaks of imported DEN and ZIKV infections were noted in 2016, and in 2019 in the case of CHIK infection. Most cases of DEN and CHIKV infections were acquired in Southeast Asia:212 (67.7%) and 15 (50%), respectively, while ZIKV infection was most commonly imported from the Caribbean (11; 57,9%). Arbovirus infections represent an increasingly significant cause of illness in Czech travellers. Comprehensive knowledge of the specific epidemiological profile of these diseases is an essential prerequisite for good travel medicine practice.